Product Information |
Product name |
Paclitaxel |
CAS No. |
33069-62-4 |
Molecular Formula |
C47H51NO14 |
Molecular Weight |
853.92 |
Quality Standard |
99% up, Medicine Grade |
Appearance |
White crystalline powder |
COA of Paclitaxel |
Appearance |
White or almost white crystalline powder |
Identification |
FT-IR |
HPLC |
|
NMR |
|
Mass |
|
Solubility |
Soluble in ethanol, methanol, Chloroform, hardly soluble in water |
Specific Optical Rotation |
-49.0º ~ -55.0º at 20°C |
Melting Point |
213°C—216°C |
Water |
≤1.0% |
Residual Solvent |
Meets the requirements of ICH |
Ethyl Acetate |
≤5000ppm |
Acetone |
≤5000ppm |
Methanol |
≤3000ppm |
Acetic acid |
≤5000ppm |
Residual of volatile Solvents |
Meets the requirements of ICH |
Chloroform |
≤60ppm |
Dichloromethane |
≤600ppm |
Hexane |
≤290ppm |
Toluene |
≤890ppm |
Residue on Ignition |
≤0.2% |
Bacteria endotoxins |
≤0.4 USP EU/mg |
Total aerobic microbial count |
≤100 cfu/g |
Staphylococcus aureus |
Absence |
Pseudomonas aeruginosa |
Absence |
Salmonella species |
Absence |
Escherichia Coli |
Absence |
Heavy Metals |
≤20 ppm |
IMPURITIES: |
|
10-Deacetyl Baccatin III |
≤0.1% |
Baccatin III |
≤0.2% |
Photodegradant |
≤0.1% |
10-Deacetyl Paclitaxel |
≤0.5% |
2-Debenzoylpaclitaxel-2-pentenoate |
≤0.7% |
Oxetane ring opened, Acetyl and benzoyl |
≤0.1% |
10-Acetoacetyl paclitaxel |
≤0.1% |
10-Deacetyl-7-epi-paclitaxel |
≤0.3% |
|
≤0.4% |
7-epi-paclitaxel |
≤0.4% |
10,13-Bissidechainpaclitaxel |
≤0.5% |
7-Acetyl Paclitaxel |
≤0.6% |
Usage |
Paclitaxel powder is
a chemotherapy drug that is given as a treatment for some types of
cancer. Paclitaxel powder is
a mitotic inhibitor now used to treat patients with lung, ovarian, breast
cancer, head and neck cancer, and advanced forms of Kaposi's sarcoma. Paclitaxel
is also used for the prevention of restenosis.
Function
of Paclitaxel
1. Paclitaxel is a mitotic
inhibitor drup used in the treatment of cancer.
2. Isolated the compound from the bark of the Pacific yew tree, Taxus
brevifolia, and noted its antitumor activity in a broad range of rodent
tumors.
3. Paclitaxel has since become an effective tool of doctors who treat patients
with lung, ovarian, breast cancer, and advanced forms of Kaposi's
sarcoma.
*Products under the patent are only for R&D use